Aenova Expands Injectables Capacity, Consolidates Network
Aenova has made a significant investment to expand its injectables capacity while consolidating the rest of its manufacturing network.
The company announced the completion of a €6 million ($6.6 million) investment at its injectables facility in Wolfratshausen, Germany. The project provided for the complete separation of cytotoxic and non-cytotoxic products at the facility; it can now handle products up to the OEB 5 exposure level, where previously it was limited to OEB 4. The improvements increased the company’s cytotoxic vial capacity to 20 million units from 12 million units. That capacity is liquid-only; it does not have cytotoxic lyophilization capacity at that site.
Aenova said it spent €45 million ($49.3 million) on capital improvements in 2014. It recently opened an expanded warehouse and logistics facility at its Tittmoning, Germany site.
Aenova grew rapidly thanks to a series of European CMO acquisitions, including Temmler in late 2012 and Haupt Pharma in early 2014. The acquisition spree left the company with a network of 24 facilities, which it has spent the last three years rationalizing. Facility closures have included:
- Bioggio, Switzerland: this site, which specialized in manufacture of effervescent tablets, was closed and production transferred to the Aenova site in Bad Aibling, Germany.
- Warstein, Germany: this solid dose site was closed and production moved to the facility in Tittmoning.
- Berlin (Wallenroder Strasse), Germany: this legacy Aenova solid dose site was closed, with production moved to Bad Aibling and Tittmoning. A second Berlin site, which was part of Haupt, remains in operation.
- Munich, Germany: the site was closed with production transferred to Bad Aibling, Tittmoning and Killorglin, Ireland.
Further consolidation may be in the offing.
This article is reprinted from the March 2015 issue of Bio/Pharmaceutical Outsourcing Report. To learn more, click here.